Infliximab treatment for refractory Kawasaki disease with coronary artery aneurysm

Circ J. 2008 May;72(5):850-2. doi: 10.1253/circj.72.850.


Tumor necrosis factor-alpha (TNF-alpha) is considered to be 1 of the factors that induce vasculitis, including coronary artery aneurysm (CA), in Kawasaki disease (KD), because the blood concentration of TNF-alpha is higher in patients with CA compared with those without. Therefore, an anti-TNF-alphaagent (infliximab) was administered to a 1-month-old girl with refractory KD complicated by CA and subsequently, the CA improved and KD was controlled without complications 20 months after the onset.

Publication types

  • Case Reports

MeSH terms

  • Anti-Inflammatory Agents / administration & dosage*
  • Antibodies, Monoclonal / administration & dosage*
  • Coronary Aneurysm / complications
  • Coronary Aneurysm / diagnostic imaging
  • Coronary Aneurysm / drug therapy*
  • Drug Resistance
  • Echocardiography
  • Female
  • Humans
  • Infant, Newborn
  • Infliximab
  • Mucocutaneous Lymph Node Syndrome / complications
  • Mucocutaneous Lymph Node Syndrome / diagnostic imaging
  • Mucocutaneous Lymph Node Syndrome / drug therapy*


  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Infliximab